ONS Chemotherapy
Immunotherapy Certificate
EXAM QUESTIONS AND
VERIFIED CORRECT
ANSWERS GRADED A+
LATEST 100% GUARANTEED
PASS
Monitoring necessary with bleomycin: - CORRECT ANSWER-Pulmonary toxicity
Hypersensitivity reactions (esp. in lymphoma patients)
Cutaneous reactions
Lifetime dose tracking (pulmonary toxicity)
Pulmonary fibrosis is possible when the lifetime dose of bleomycin exceeds: - CORRECT
ANSWER-400 units
What 6 patient characteristics make CINV more likely? - CORRECT ANSWER-1. Younger than 50
years
2. Hx of low alcohol intake
3. Female gender
4. Hx of morning sickness during pregnancy
5. Prone to motion sickness
6. Previous chemotherapy
,Types of CINV: - CORRECT ANSWER-Acute
Delayed
Breakthrough
Anticipatory
Refractory
Define acute CINV - CORRECT ANSWER-Occurring within 24 hours of chemotherapy
Define delayed CINV - CORRECT ANSWER-Occurring from 24 hours to 5 days after treatment
Define breakthrough CINV - CORRECT ANSWER-Occurring despite treatment
Define anticipatory CINV - CORRECT ANSWER-Triggered by taste, odor, memories, visions, or
anxiety related to chemotherapy
Define refractory CINV - CORRECT ANSWER-Occurring during subsequent cycles when
treatment failed in earlier cycles
Moderately emetogenic chemo (MEC) causes CINV in patients ___% to ___% of the time -
CORRECT ANSWER-30-90
Patients on low-potential emetogenic chemo develop CINV ___% to ___% of the time -
CORRECT ANSWER-10-30
Minimal-risk emetogenic chemo causes CINV less than ___% of the time - CORRECT ANSWER-10
, Common IV HEC drugs include: - CORRECT ANSWER-Carmustine
Cisplatin
Cyclophosphamide
Dacarbazine
Mechlorethamine
Streptozosin
Common IV MEC drugs include: - CORRECT ANSWER-Carboplatin
Cytarabine
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Ifosfamide
Irinotecan
Oxaliplatin
Common low-potential IV emetogenic chemo drugs include: - CORRECT ANSWER-5-FU
Cytarabine
Docetaxel
Etoposide
Gemcitabine
Methotrexate
Mitomycin C
Mitoxantrone
Paclitaxel
Immunotherapy Certificate
EXAM QUESTIONS AND
VERIFIED CORRECT
ANSWERS GRADED A+
LATEST 100% GUARANTEED
PASS
Monitoring necessary with bleomycin: - CORRECT ANSWER-Pulmonary toxicity
Hypersensitivity reactions (esp. in lymphoma patients)
Cutaneous reactions
Lifetime dose tracking (pulmonary toxicity)
Pulmonary fibrosis is possible when the lifetime dose of bleomycin exceeds: - CORRECT
ANSWER-400 units
What 6 patient characteristics make CINV more likely? - CORRECT ANSWER-1. Younger than 50
years
2. Hx of low alcohol intake
3. Female gender
4. Hx of morning sickness during pregnancy
5. Prone to motion sickness
6. Previous chemotherapy
,Types of CINV: - CORRECT ANSWER-Acute
Delayed
Breakthrough
Anticipatory
Refractory
Define acute CINV - CORRECT ANSWER-Occurring within 24 hours of chemotherapy
Define delayed CINV - CORRECT ANSWER-Occurring from 24 hours to 5 days after treatment
Define breakthrough CINV - CORRECT ANSWER-Occurring despite treatment
Define anticipatory CINV - CORRECT ANSWER-Triggered by taste, odor, memories, visions, or
anxiety related to chemotherapy
Define refractory CINV - CORRECT ANSWER-Occurring during subsequent cycles when
treatment failed in earlier cycles
Moderately emetogenic chemo (MEC) causes CINV in patients ___% to ___% of the time -
CORRECT ANSWER-30-90
Patients on low-potential emetogenic chemo develop CINV ___% to ___% of the time -
CORRECT ANSWER-10-30
Minimal-risk emetogenic chemo causes CINV less than ___% of the time - CORRECT ANSWER-10
, Common IV HEC drugs include: - CORRECT ANSWER-Carmustine
Cisplatin
Cyclophosphamide
Dacarbazine
Mechlorethamine
Streptozosin
Common IV MEC drugs include: - CORRECT ANSWER-Carboplatin
Cytarabine
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Ifosfamide
Irinotecan
Oxaliplatin
Common low-potential IV emetogenic chemo drugs include: - CORRECT ANSWER-5-FU
Cytarabine
Docetaxel
Etoposide
Gemcitabine
Methotrexate
Mitomycin C
Mitoxantrone
Paclitaxel
